Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Apogee Therapeutics Inc shares valued at $1,455,613 were sold by Dambkowski Carl on Jan 07 ’26. At $77.84 per share, Dambkowski Carl sold 18,700 shares. The insider’s holdings dropped to 212,523 shares worth approximately $17.16 million following the completion of this transaction.
Also, CARL DAMBKOWSKI purchased 35,200 shares, netting a total of over 2,754,400 in proceeds.
Before that, Henderson Jane had sold 6,000 shares from its account. In a trade valued at $449,146, the Chief Financial Officer traded Apogee Therapeutics Inc shares for $74.86 each. Upon closing the transaction, the insider’s holdings decreased to 6,000 shares, worth approximately $15.13 million.
As published in their initiating research note from Wolfe Research on January 07, 2026, Apogee Therapeutics Inc [APGE] has been a Peer perform. Analysts at Stephens started covering the stock with ‘”an Overweight”‘ outlook in a report released in mid December. As of December 10, 2025, Deutsche Bank has initiated its “Buy” rating for APGE. Earlier on November 03, 2025, Craig Hallum initiated its rating. Their recommendation was “a Buy” for APGE stock.
Analyzing APGE Stock Performance
On last trading session, Apogee Therapeutics Inc [NASDAQ: APGE] plunged -2.04% to $80.75. The stock’s lowest price that day was $80.553, but it reached a high of $83.24 in the same session. During the last five days, there has been a surge of approximately 4.22%. Over the course of the year, Apogee Therapeutics Inc shares have jumped approximately 105.26%.
Support And Resistance Levels for Apogee Therapeutics Inc (APGE)
RSI (Relative Strength Index) is 64.47 on the 14-day chart, showing neutral technical sentiment.
Is Apogee Therapeutics Inc subject to short interest?
Stocks of Apogee Therapeutics Inc saw a sharp rise in short interest on 2025-12-31 jumping by 0.77 million shares to 8.66 million. Data from Yahoo Finance shows that the short interest on 2025-11-28 was 7.9 million shares. A jump of 8.84% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just 8.92 of the overall float, the days-to-cover ratio (short ratio) jumped to 8.92.
Which companies own the most shares of Apogee Therapeutics Inc (APGE)?
In terms of Apogee Therapeutics Inc share price expectations, FactSet research, analysts set an average price target of 109.5 in the next 12 months, up nearly 32.84% from the previous closing price of $82.43. Analysts anticipate Apogee Therapeutics Inc stock to reach 137 by 2026, with the lowest price target being 60. On October 21, 2025, Mizuho assigned a price target of “an Outperform” to the stock and initiated coverage with a $105.
